002603 以岭藥業
按盤價 
15.600 +0.550 (+3.654%)
15.600 +0.550 (+3.654%) | 2026/03 - 三個月 人民幣(K¥) | 與去年同期 比較 | 2025/12 人民幣(K¥) | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | ||
| 營業總收入 | 2,439,784 | 3.46% | 7,830,737 | 6,512,734 | 10,318,313 | 12,532,841 | |
| 減：營業總成本 | 1,941,982 | -0.25% | 6,149,555 | 7,147,123 | 8,719,196 | 9,666,882 | |
| 其中:營業成本 | 974,597 | -10.50% | 2,797,410 | 3,244,209 | 4,407,809 | 4,540,572 | |
| 財務費用 | 1,781 | -309.04% | (1,410) | 22,415 | 26,368 | 19,920 | |
| 資產減值損失 | (3,525) | -82.57% | (148,273) | (248,337) | (35,358) | (108,432) | |
| 公允價值變動收益 | 848 | -- | 3,923 | -- | 39,354 | 18,734 | |
| 投資收益 | 4,349 | -977.40% | 2,074 | 39,808 | 25,950 | (7,229) | |
| 其中：對聯營企業和合營企業的投資收益 | (3) | 0.96% | (11) | (11) | (15) | (3) | |
| 營業利潤 | 499,741 | 25.38% | 1,623,431 | (688,895) | 1,779,828 | 2,829,555 | |
| 利潤總額 | 489,099 | 24.10% | 1,591,611 | (800,192) | 1,684,211 | 2,780,643 | |
| 減：所得稅費用 | 80,487 | 15.04% | 309,881 | (66,008) | 339,909 | 422,870 | |
| 淨利潤 | 408,612 | 26.05% | 1,281,730 | (734,184) | 1,344,303 | 2,357,773 | |
| 減：非控股權益 | (236) | -86.88% | (4,749) | (9,668) | (8,077) | (4,983) | |
| 股東淨利潤 | 408,848 | 25.43% | 1,286,479 | (724,516) | 1,352,379 | 2,362,756 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.245 | 25.42% | 0.770 | -0.434 | 0.810 | 1.414 | |
| 每股派息 (元) * | -- | -- | 0.800 | -- | 0.300 | 0.500 | |
| 每股淨資產 (元) * | 6.822 | 8.05% | 6.578 | 6.119 | 6.853 | 6.543 | |
| 審計意見 # | -- | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 23/06/2026 09:53 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
